E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms
Lakshmikanth Katragadda,Hagop M. Kantarjian,Guillermo Garcia-Manero,Tapan M. Kadia,Alessandra Ferrajoli,Elias Jabbour,Alfonso Quintás-Cardama,Marina Konopleva,Manoj Maniar,Francois Wilhelm,Farhad Ravandi,Jorge E. Cortes +11 more
TL;DR: A study in acute myeloid leukemia (AML) investigating alternative schedules to determine the optimal dose and anti-leukemia efficacy and serious adverse events seen were altered mental status, confusion, delirium, acute respiratory distress, and febrile neutropenia.
Journal ArticleDOI
Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission
Armin Ghobadi,Kahee A. Mohammed,Rawan Faramand,Hagop M. Kantarjian,Elias Jabbour,Nicholas J. Short,Feng Gao,Geoffrey L. Uy,Peter Westervelt,John F. DiPersio,Richard E. Champlin,Farhad Ravandi,Partow Kebriaei +12 more
TL;DR: A multi-institutional, retrospective analysis of 186 patients ≥18 years of age who received induction therapy including TKI for Ph+ ALL from January 2001 through December 2018 shows that adult patients with Ph+ALL in CR1 in CMR have similar estimates of OS and RFS.
Journal ArticleDOI
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
Farhad Ravandi,Susan O'Brien,Rebecca Garris,Stefan Faderl,Deborah A. Thomas,Jan A. Burger,Alessandra Ferrajoli,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian +9 more
TL;DR: This phase II trial determined the long-term efficacy of the combination of the hyperCVAD regimen with dasatinib for treating patients with Ph+ ALL and found that 45 patients have achieved complete molecular remission (CMR) and another 19 have achieved a major (but not complete) molecular response (MMR).
Journal ArticleDOI
Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-than-Complete Response After First Salvage Therapy
Shilpan Shah,Hagop M. Kantarjian,Farhad Ravandi,Susan O'Brien,Guillermo Garcia-Manero,Michael Andreef,Marina Konopleva,Elias Jabbour,Sherry Pierce,Gautam Borthakur,Jorge E. Cortes +10 more
TL;DR: If less-than-complete remissions (CRi) after salvage therapy impact overall survival in relapsed or refractory AML patients when compared to complete remission and no response is evaluated.
Journal ArticleDOI
Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts
Carlos Guillermo Romo,Hagop M. Kantarjian,Rajyalakshmi Luthra,Alfonso Quintás-Cardama,Elias Jabbour,Gautam Borthakur,Tapan M. Kadia,Farhad Ravandi,Naveen Pemmaraju,Sherry Pierce,Susan O'Brien,Jorge E. Cortes +11 more
TL;DR: Those with b3a2 have a significantly higher rate of molecular responses and a trend for better EFS, compared with those with b2a2 whether they express b3A2 or b2A2 at diagnosis, which warrant further investigation.